CN1655675A - 利用三叶肽的联合治疗 - Google Patents

利用三叶肽的联合治疗 Download PDF

Info

Publication number
CN1655675A
CN1655675A CNA038120402A CN03812040A CN1655675A CN 1655675 A CN1655675 A CN 1655675A CN A038120402 A CNA038120402 A CN A038120402A CN 03812040 A CN03812040 A CN 03812040A CN 1655675 A CN1655675 A CN 1655675A
Authority
CN
China
Prior art keywords
composition
trefoil
trefoil peptide
cys
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038120402A
Other languages
English (en)
Chinese (zh)
Inventor
D·K·波多尔斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN1655675A publication Critical patent/CN1655675A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA038120402A 2002-03-26 2003-03-26 利用三叶肽的联合治疗 Pending CN1655675A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36757402P 2002-03-26 2002-03-26
US60/367,574 2002-03-26
US42270802P 2002-10-31 2002-10-31
US60/422,708 2002-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101808237A Division CN101152563A (zh) 2002-03-26 2003-03-26 利用三叶肽的联合治疗

Publications (1)

Publication Number Publication Date
CN1655675A true CN1655675A (zh) 2005-08-17

Family

ID=28678188

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038120402A Pending CN1655675A (zh) 2002-03-26 2003-03-26 利用三叶肽的联合治疗

Country Status (8)

Country Link
US (1) US20030186880A1 (enExample)
EP (1) EP1494530A4 (enExample)
JP (1) JP2005527547A (enExample)
CN (1) CN1655675A (enExample)
AU (1) AU2003224773B2 (enExample)
CA (1) CA2480372A1 (enExample)
MX (1) MXPA04009363A (enExample)
WO (1) WO2003082196A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381560C (zh) * 2005-09-27 2008-04-16 中国人民解放军第三军医大学第一附属医院 采用gs115酵母菌合成重组人肠三叶因子的工艺

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
CA2462291A1 (en) * 2001-10-05 2003-04-17 The General Hospital Corporation Methods and compositions for treating dermal lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
AU2003286844A1 (en) * 2002-10-31 2004-05-25 The General Hospital Corporation Trefoil domain-containing polypeptides and uses thereof
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
WO2013176785A1 (en) 2012-05-21 2013-11-28 The Trustees Of Columbia University In The City Of New York Trefoil family factor and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN108135970B (zh) 2015-09-09 2023-09-01 弗莱德哈钦森癌症中心 软骨归巢肽
WO2018049285A1 (en) 2016-09-09 2018-03-15 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof
AU2018210157B2 (en) 2017-01-18 2022-10-06 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3595699A4 (en) 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
CA3064436A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
AU2018388583A1 (en) 2017-12-19 2020-06-11 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
EP4137209A4 (en) * 2020-03-30 2023-08-30 Shandong Ruiying Pioneer Pharmaceuticals Co., Ltd. APPLICATION OF A COMBINATION OF TFF2 PROTEIN AND IFN-? IN THE TREATMENT OF A NEW CORONAVIRUS INFECTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151472A (en) * 1874-06-02 Improvement in rotary engines
US4370317A (en) * 1980-09-10 1983-01-25 Novo Industri A/S Pancreatic spasmolytic polypeptide
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
DK6893D0 (da) * 1993-01-21 1993-01-21 Novo Nordisk As Peptid
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CA2196876C (en) * 1994-08-26 2007-04-17 Lars Thim Trefoil peptide dimer
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030078205A1 (en) * 2001-07-31 2003-04-24 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
WO1999010377A1 (en) * 1997-08-25 1999-03-04 The General Hospital Corporation Receptor for intestinal trefoil factor
KR20010072931A (ko) * 1998-08-26 2001-07-31 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 폐 질환 치료 요법
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
AU781679B2 (en) * 1999-07-05 2005-06-09 Intrexon Actobiotics Nv Delivery of trefoil peptides
US20030040478A1 (en) * 1999-12-08 2003-02-27 Drucker Daniel J Chemotherapy treatment
WO2001046475A1 (en) * 1999-12-23 2001-06-28 Human Genome Sciences, Inc. Trefoil domain-containing polynucleotides, polypeptides, and antibodies
EP1343492B1 (en) * 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
EP1383527A4 (en) * 2001-04-24 2004-07-14 Gen Hospital Corp METHOD AND COMPOSITIONS FOR TREATING ORAL AND EYE EYE LESIONS
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US7538082B2 (en) * 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
JP2004534801A (ja) * 2001-06-14 2004-11-18 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆｆ２ペプチドによる粘膜修復
US20030153496A1 (en) * 2001-06-14 2003-08-14 Lars Thim Mucosal repair by TFF dimer peptides
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
CA2462291A1 (en) * 2001-10-05 2003-04-17 The General Hospital Corporation Methods and compositions for treating dermal lesions
MXPA04005053A (es) * 2001-11-28 2004-09-10 Gen Hospital Corp Metodos y composiciones para tratar lesiones del epitelio respiratorio.
US20030215431A1 (en) * 2002-02-11 2003-11-20 Lars Thim Management of mucosal viscosity by TFF monomer peptides
US6780383B1 (en) * 2003-02-28 2004-08-24 Eugene Ettlinger System for sterilization of spaces and surfaces
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2006124681A2 (en) * 2005-05-18 2006-11-23 The Gi Company, Inc. Oral drug delivery system and methods of use thereof
US7575920B2 (en) * 2005-07-25 2009-08-18 The Gi Company, Inc. Yeast expression vectors for production of ITF

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381560C (zh) * 2005-09-27 2008-04-16 中国人民解放军第三军医大学第一附属医院 采用gs115酵母菌合成重组人肠三叶因子的工艺

Also Published As

Publication number Publication date
AU2003224773B2 (en) 2010-08-26
WO2003082196A3 (en) 2003-12-04
EP1494530A4 (en) 2009-06-24
CA2480372A1 (en) 2003-10-09
AU2003224773A1 (en) 2003-10-13
WO2003082196A2 (en) 2003-10-09
EP1494530A2 (en) 2005-01-12
MXPA04009363A (es) 2005-01-25
US20030186880A1 (en) 2003-10-02
JP2005527547A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
CN1655675A (zh) 利用三叶肽的联合治疗
JP4477013B2 (ja) 線維芽細胞成長因子２１の突然変異タンパク質
JP5907970B2 (ja) インターロイキン−２２のウイルス性肝炎の治療における応用
CN116063454A (zh) 胰高血糖素/glp-1/gip受体三重激动剂
CN1303381A (zh) 二肽基肽酶iv的新效应物
CN1599619A (zh) 治疗真皮损伤的方法和组合物
CN1520309A (zh) 治疗口腔及食道损伤的方法和组合物
CN1561224A (zh) 降低与严重疾病相关的死亡率和发病率的方法
CN101056647A (zh) 肠血管活性多肽药物
CN1202112A (zh) 增强胰腺功能的组合物
CN1541103A (zh) 诱导持续免疫应答的方法
CN1533808A (zh) 治疗冠状病毒感染和sars的组合物与方法
CN1615154A (zh) 干扰素tau的口服给药
CN1178660C (zh) 抗病毒药物组合
CN101039696A (zh) 给药人il－18治疗创伤的方法
CN1703244A (zh) Ppar配体和抗氧剂间的联合及其用于治疗肥胖的用途
CN1191271C (zh) 干扰素－胸腺肽融合蛋白及其制法
HK1081401A (en) Combination therapy using trefoil peptides
CN1681806A (zh) 酰氧基吡咯烷衍生物,其制备及其在治疗学上的应用
CN101152563A (zh) 利用三叶肽的联合治疗
Feng et al. Two ACTH analogs exert differential effects on monocytes/macrophages function regulation in ayu (Plecoglossus altivelis)
CN1684705A (zh) 使用具有preptin功能的化合物的方法
CN1294987C (zh) 心肌肌钙蛋白i在制备抑制肿瘤药物中的应用
CN1029771C (zh) 斑蝥素脂溶性制剂的制备
CN1286526C (zh) 一种抗癌药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081401

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050817

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081401

Country of ref document: HK